Intensiveret behandling at type 2-diabetes mellitus: Er polyfarmaci nødvendig og berettiget?

Translated title of the contribution: Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?

O B Pedersen, P H Gaede

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Newly published randomised controlled trials with pharmacological intervention against hyperglycaemia, hypertension and dyslipidemia have challenged the traditional empiric treatment of type 2-diabetes. This review focuses on the results of these trials as well as randomised trials with pharmacological therapy of microalbuminuria, primary prevention with acetylsalicylic acid and angiotensin converting enzyme (ACE) inhibitors. The overall results from these trials are clinically relevant reductions in the risk of late diabetic complications. Taken together, the new clinical knowledge does not mean that all patients with type 2-diabetes besides relevant changes in lifestyle will benefit from a comprehensive polypharmacy. It means, however, that based upon the individual risk profile the medical professionals have to motivate the patient for an evidence based "therapeutic package" which is likely to improve the longterm outcome.

Translated title of the contributionIntensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified?
Original languageDanish
JournalUgeskrift for Laeger
Volume162
Issue number25
Pages (from-to)3582-3591
ISSN0041-5782
Publication statusPublished - 19. Jun 2000
Externally publishedYes

Keywords

  • English Abstract
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Fingerprint Dive into the research topics of 'Intensified treatment of type 2 diabetes mellitus. Is polypharmacy necessary and justified? Er polyfarmaci nødvendig og berettiget?'. Together they form a unique fingerprint.

Cite this